Physician profile
John Mark Cappleman
NPI 1790783389
$10,351.45
in general payments reported to CMS, 2019-2025
42 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 90% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $799 · 2020: $1,333 · 2021: $2,725 · 2022: $1,334 · 2023: $1,621 · 2024: $1,392 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,108 · Education: $51.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,108.48 |
| Education | $51.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,399.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,293.55 | 2021 | |
| Pfizer INC. | $1,195.84 | 2019-2025 | |
| Lilly USA, LLC | $850.20 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $810.06 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $516.28 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $488.19 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $394.80 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $392.30 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $287.72 | 2021-2025 | |
| Exact Sciences Corporation | $259.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $228.10 | 2019-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $204.01 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $193.87 | 2022 | |
| Phathom Pharmaceuticals, INC. | $191.65 | 2023-2025 | Voquezna |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cappleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.